ZYNERBA PHARMACEUTICALS INC's ticker is ZYNE and the CUSIP is 98986X109. A total of 80 filers reported holding ZYNERBA PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 2.65 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $280 | +294.4% | 220,858 | 0.0% | 0.01% | +500.0% |
Q2 2023 | $71 | -24.5% | 220,858 | +0.8% | 0.00% | -50.0% |
Q1 2023 | $94 | -17.5% | 219,146 | +1.6% | 0.00% | -33.3% |
Q4 2022 | $114 | -99.9% | 215,722 | +1.6% | 0.00% | -25.0% |
Q3 2022 | $155,000 | -61.1% | 212,298 | -39.2% | 0.00% | -63.6% |
Q2 2022 | $398,000 | -44.6% | 349,336 | -0.5% | 0.01% | -35.3% |
Q1 2022 | $719,000 | -39.1% | 351,154 | -14.4% | 0.02% | -32.0% |
Q4 2021 | $1,180,000 | -26.8% | 410,062 | +7.7% | 0.02% | -24.2% |
Q3 2021 | $1,613,000 | -18.1% | 380,698 | +2.2% | 0.03% | -8.3% |
Q2 2021 | $1,969,000 | +18.8% | 372,384 | +4.3% | 0.04% | +16.1% |
Q1 2021 | $1,658,000 | +290.1% | 356,876 | +176.1% | 0.03% | +210.0% |
Q4 2020 | $425,000 | +98.6% | 129,252 | +98.8% | 0.01% | +25.0% |
Q3 2020 | $214,000 | -32.9% | 65,002 | -31.5% | 0.01% | -50.0% |
Q2 2020 | $319,000 | -5.1% | 94,962 | +8.0% | 0.02% | -30.4% |
Q1 2020 | $336,000 | +168.8% | 87,942 | +250.0% | 0.02% | +187.5% |
Q4 2019 | $125,000 | -11.3% | 25,128 | +34.2% | 0.01% | -33.3% |
Q3 2019 | $141,000 | – | 18,726 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RA Capital Management | 507,191 | $5,107,000 | 0.50% |
Cormorant Asset Management, LP | 356,600 | $3,591,000 | 0.43% |
Perceptive Advisors | 558,446 | $5,623,000 | 0.42% |
NEXTHERA CAPITAL LP | 15,000 | $151,000 | 0.21% |
EMERALD ADVISERS, LLC | 237,070 | $2,387,000 | 0.11% |
AUXIER ASSET MANAGEMENT | 17,857 | $180,000 | 0.04% |
FEDERATED HERMES, INC. | 450,000 | $4,532,000 | 0.01% |
Nationwide Fund Advisors | 49,473 | $498,000 | 0.00% |
Catalyst Capital Advisors LLC | 348 | $4,000 | 0.00% |
DEUTSCHE BANK AG\ | 859 | $8,000 | 0.00% |